The effect of gadolinium-based contrast agents (GBCAs) on dynamic PET quantification was investigated. Simultaneous PET/MRI was performed in patients with biopsy confirmed invasive breast cancer. Subjects received an injection of a GBCA as part of standard clinical dynamic contrast enhanced breast MRI exam. SUVmean and SUVmax were calculated for the biopsy-proven breast cancer, aorta, liver, and benign fibroglandular tissue prior to and following GBCA injection. No significant difference in SUVmean or SUVmax was measured suggesting GBCAs are unlikely to affect PET quantification in combined breast PET/MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords